Expression of HPV6b L1/EBV LMP2 multiepitope and immunogenicity in mice

Acta Biochimica et Biophysica Sinica

Volumn 42, Issue 8, 2010, Pages 515-521

  Zhu, Shanli ^a   Xue, Xiangyang ^a   Liu, Jianxiao ^a   Lu, Lijun ^a   Zhao, Pengyun ^a   Wang, Jia ^a   Li, Wenshu ^a   Zhang, Lifang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

epitope; epstein Barr virus; human papillomavirus; latency membrane protein

Indexed keywords

CAPSID PROTEIN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EPITOPE; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; HYBRID PROTEIN; MATRIX PROTEIN; ONCOPROTEIN; VIRUS ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL STRAIN COS1; CELL SURVIVAL; CERCOPITHECUS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNIZATION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MOUSE; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; CAPSID PROTEINS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS 6; IMMUNIZATION; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PLASMIDS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4; HUMAN PAPILLOMAVIRUS; MAMMALIA; MIRIDAE; MUS;

EID: 77955201339     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq054     Document Type: Article

References (28)

1. Zur Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1996, 1288: F55-F78. (Pubitemid 26335492)
2. Trottier H and Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009, 12: 291-307.
3. Cutts FT, Franceschi S, Goldie S, Castellsague X, Sanjose S, Garnett G and Edmunds WJ, et al. Human papillomavirus and HPV vaccines. Bull World Health Org 2007, 85: 719-726.
4. Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J and Braspenning J, et al. Chimeric papillomavirus-like particles. Virology 1997, 234: 93-111.
5. Freyschmidt EJ, Alonso A, Hartmann G and Gissmann L. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther 2004, 9: 479-489.
6. Paz De la Rosa G, Monroy-García A, Mora-García Mde L, Peña CG, Hernández-Montes J, Weiss-Steider B and Gómez-Lim MA. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J 2009, 6: 2.
7. Liu WJ, Liu XS, Zhao KN, Leggatt GR and Frazer IH. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 2000, 273: 374-382.
8. Peng S, Frazer IH, Fernando GJ and Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 1998, 240: 147-157.
9. Slupetzky K, Shafti-Keramat S, Lenz P, Brandt S, Grassauer A, Sara M and Kirnbauer R. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 2001, 82: 2799-2804.
10. Zhang H, Huang Y, Fayad R, Spear GT and Qiao L. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol 2004, 78: 8342-8348.
11. Sung NS, Edwards RH, Seillier-Moiseiwitsch F, Perkins AG, Zeng Y and Raab-Traub N. Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int J Cancer 1998, 76: 207-215.
12. Shah KM and Young LS. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Clin Microbiol Infect 2009, 15: 982-988.
13. Pang MF, Lin KW and Peh SC. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer. Cell Mol Biol Lett 2009, 14: 222-247.
14. Lalonde A, Avila-Carino J, Caruso M and de Campos-Lima PO. Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein-Barr virus latent membrane protein 2. Virology 2007, 361: 253-262.
15. Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE and Rooney CM, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol 2005, 175: 4137-4147.
16. Wang B, Yao K, Liu G, Xie F, Zhou F and Chen Y. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes. Cell Mol Immunol 2009, 6: 97-103.
17. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS and Rowe M, et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 1993, 67: 7428-7435.
18. Lee SP, Tierney RJ, Thomas WA, Brooks JM and Rickinson AB. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 1997, 158: 3325-3334.
19. Kuzushima K, Hayashi N, Kudoh A, Akatsuka Y, Tsujimura K, Morishima Y and Tsurumi T. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells. Blood 2003, 101: 1460-1468.
20. Zhou J, Liu WJ, Peng SW, Sun XY and Frazer I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol 1999, 73: 4972-4982.
21. Ou Q, Zhu SL and Zhang LF. Prediction of the secondary structure and B-cell epitopeS of EBV LMP2. J Wenzhou Med Coll 2007, 37: 114-118.
22. Kodama H, Denso, Okazaki F and Ishida S. Protective effect of humus extract against Trypanosoma brucei infection in mice. J Vet Med Sci 2008, 70: 1185-1190.
23. Windram OP, Weber B, Jaffer MA, Rybicki EP, Shepherd DN and Varsani A. An investigation into the use of human papillomavirus type 16 virus-like particles as a delivery vector system for foreign proteins: N- and C-terminal fusion of GFP to the L1 and L2 capsid proteins. Arch Virol 2008, 153: 585-589.
24. Mossadegh N, Gissmann L, Müller M, Zentgraf H, Alonso A and Tomakidi P. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 2004, 326: 57-66.
25. Johnson AG. Molecular adjuvants and immunomodulators: new approaches to immunization. Clin Microbiol Rev 1994, 7: 277-289.
26. Rocha-Zavaleta L, Alejandre JE and Garcia-Carranca A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 2002, 66: 86-95.
27. Matsumoto K, Kawana K, Yoshikawa H, Taketani Y, Yoshiike K and Kanda T. DNA vaccination of mice with plasmid expressing human papillomavirus major capsid protein L1 elicits type-specific antibodies neutralizing pseudovirions constructed in vitro. J Med Virol 2000, 60: 200-204.
28. Gasparić M, Rubio I, Thönes N, Gissmann L and Müller M. Prophylactic DNA immunization against multiple papillomavirus types. Vaccine 2007, 25: 4540-4553.